vs
Pacira BioSciences, Inc.（PCRX）与BOSTON BEER CO INC（SAM）财务数据对比。点击上方公司名可切换其他公司
BOSTON BEER CO INC的季度营收约是Pacira BioSciences, Inc.的2.6倍（$461.6M vs $177.4M），Pacira BioSciences, Inc.同比增速更快（5.0% vs -4.1%），过去两年Pacira BioSciences, Inc.的营收复合增速更高（-0.2% vs -10.7%）
Pacira BioSciences是一家专科制药企业，专注于非阿片类疼痛管理药物的研发与商业化，核心产品线面向术后镇痛场景，服务以美国为主的医院、门诊手术中心等医疗服务机构，同时推进部分国际市场的拓展工作。
波士顿啤酒公司是美国知名酿酒企业，1984年由吉姆·科赫与朗达·卡尔曼联合创立。旗下首款产品以美国开国元勋、独立运动先驱塞缪尔·亚当斯命名，后续陆续推出多个自有品牌，2019年正式完成与角鲨头酿酒厂的合并，是北美精酿啤酒行业的核心参与者之一。
PCRX vs SAM — 直观对比
营收规模更大
SAM
是对方的2.6倍
$177.4M
营收增速更快
PCRX
高出9.1%
-4.1%
两年增速更快
PCRX
近两年复合增速
-10.7%
损益表 — Q1 FY2026 vs Q1 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $177.4M | $461.6M |
| 净利润 | $2.9M | — |
| 毛利率 | — | 46.4% |
| 营业利润率 | 3.9% | 12.4% |
| 净利率 | 1.6% | — |
| 营收同比 | 5.0% | -4.1% |
| 净利润同比 | — | — |
| 每股收益（稀释后） | $0.07 | $2.16 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收PCRXSAM
| Q1 26 | $177.4M | $461.6M | ||
| Q4 25 | $196.9M | $385.7M | ||
| Q3 25 | $179.5M | $537.5M | ||
| Q2 25 | $181.1M | $587.9M | ||
| Q1 25 | $168.9M | $453.9M | ||
| Q4 24 | $187.3M | $402.3M | ||
| Q3 24 | $168.6M | $605.5M | ||
| Q2 24 | $178.0M | $579.1M |
净利润PCRXSAM
| Q1 26 | $2.9M | — | ||
| Q4 25 | — | $-22.5M | ||
| Q3 25 | $5.4M | $46.2M | ||
| Q2 25 | $-4.8M | $60.4M | ||
| Q1 25 | $4.8M | $24.4M | ||
| Q4 24 | — | $-38.8M | ||
| Q3 24 | $-143.5M | $33.5M | ||
| Q2 24 | $18.9M | $52.3M |
毛利率PCRXSAM
| Q1 26 | — | 46.4% | ||
| Q4 25 | 79.5% | 43.5% | ||
| Q3 25 | 80.9% | 50.8% | ||
| Q2 25 | 77.4% | 49.8% | ||
| Q1 25 | 79.7% | 48.3% | ||
| Q4 24 | 78.7% | 39.9% | ||
| Q3 24 | 76.9% | 46.3% | ||
| Q2 24 | 75.1% | 46.0% |
营业利润率PCRXSAM
| Q1 26 | 3.9% | 12.4% | ||
| Q4 25 | 1.2% | -8.6% | ||
| Q3 25 | 3.5% | 11.5% | ||
| Q2 25 | 4.7% | 14.0% | ||
| Q1 25 | 1.2% | 7.4% | ||
| Q4 24 | 13.2% | -13.9% | ||
| Q3 24 | -82.8% | 7.6% | ||
| Q2 24 | 15.9% | 12.2% |
净利率PCRXSAM
| Q1 26 | 1.6% | — | ||
| Q4 25 | — | -5.8% | ||
| Q3 25 | 3.0% | 8.6% | ||
| Q2 25 | -2.7% | 10.3% | ||
| Q1 25 | 2.8% | 5.4% | ||
| Q4 24 | — | -9.6% | ||
| Q3 24 | -85.1% | 5.5% | ||
| Q2 24 | 10.6% | 9.0% |
每股收益（稀释后）PCRXSAM
| Q1 26 | $0.07 | $2.16 | ||
| Q4 25 | $0.05 | $-1.97 | ||
| Q3 25 | $0.12 | $4.25 | ||
| Q2 25 | $-0.11 | $5.45 | ||
| Q1 25 | $0.10 | $2.16 | ||
| Q4 24 | $0.38 | $-3.23 | ||
| Q3 24 | $-3.11 | $2.86 | ||
| Q2 24 | $0.39 | $4.39 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $144.3M | $164.1M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $653.9M | $682.6M |
| 总资产 | $1.2B | $1.2B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资PCRXSAM
| Q1 26 | $144.3M | $164.1M | ||
| Q4 25 | $238.4M | $223.4M | ||
| Q3 25 | $246.3M | $250.5M | ||
| Q2 25 | $445.9M | $212.4M | ||
| Q1 25 | $493.6M | $152.5M | ||
| Q4 24 | $484.6M | $211.8M | ||
| Q3 24 | $453.8M | $255.6M | ||
| Q2 24 | $404.2M | $219.3M |
总债务PCRXSAM
| Q1 26 | — | — | ||
| Q4 25 | $372.2M | — | ||
| Q3 25 | $376.7M | — | ||
| Q2 25 | $580.5M | — | ||
| Q1 25 | $583.4M | — | ||
| Q4 24 | $585.3M | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
股东权益PCRXSAM
| Q1 26 | $653.9M | $682.6M | ||
| Q4 25 | $693.1M | $846.3M | ||
| Q3 25 | $727.2M | $911.0M | ||
| Q2 25 | $757.8M | $912.3M | ||
| Q1 25 | $798.5M | $897.0M | ||
| Q4 24 | $778.3M | $916.2M | ||
| Q3 24 | $749.6M | $1.0B | ||
| Q2 24 | $879.3M | $1.0B |
总资产PCRXSAM
| Q1 26 | $1.2B | $1.2B | ||
| Q4 25 | $1.3B | $1.2B | ||
| Q3 25 | $1.3B | $1.2B | ||
| Q2 25 | $1.5B | $1.3B | ||
| Q1 25 | $1.6B | $1.2B | ||
| Q4 24 | $1.6B | $1.3B | ||
| Q3 24 | $1.5B | $1.4B | ||
| Q2 24 | $1.6B | $1.4B |
负债/权益比PCRXSAM
| Q1 26 | — | — | ||
| Q4 25 | 0.54× | — | ||
| Q3 25 | 0.52× | — | ||
| Q2 25 | 0.77× | — | ||
| Q1 25 | 0.73× | — | ||
| Q4 24 | 0.75× | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
PCRX
| EXPAREL | $143.3M | 81% |
| ZILRETTA | $26.8M | 15% |
| iovera° | $6.2M | 3% |
| Bupivacaine liposome injectable suspension | $1.2M | 1% |
SAM
暂无分部数据
